Drug intelligence / Profile preview

NEED

Development stage: Preclinical
Lead developer: RIGImmune
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intranasal, Inhalation, Ophthalmic, Intravitreal

Overview

NEED™ (Nano-Emulsion Enhanced Delivery) is a proprietary drug delivery platform developed by RIGImmune. It utilizes a nano-emulsion formulation designed to enhance the mucosal and ocular delivery and uptake of therapeutic agents. The technology is being applied to several preclinical programs, including the intranasal delivery of therapeutics for the prevention of asthma exacerbations caused by viral infections, solutions for inhalation to treat rare pulmonary diseases, and intravitreal or eyedrop formulations for ocular diseases. By improving the bioavailability and localized delivery of drugs, NEED™ aims to optimize treatment efficacy for respiratory and ophthalmic conditions.

Brand names: NEED
Other names: Nano-Emulsion Enhanced Delivery

Beyond the preview

Go deeper on NEED.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEED.

Explore the full profile